NCT02025010 - Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 27, 2014

Primary Completion Date

December 31, 2021

Study Completion Date

April 7, 2025

Conditions

Castration-resistant Prostate Cancer

Interventions

DRUG

abiraterone acetate

Abiraterone acetate is a selective and irreversible inhibitor of CYP17 which has demonstrated clinical efficacy in patients with CRPC. Currently, AA is administered with concomitant prednisone.

Trial Locations (8)

10065

Memorial Sloan-Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Cancer Center Sleepy Hollow, Sleepy Hollow

10604

Memorial Sloan Kettering Cancer Center West Harrison, Harrison

11510

Memorial Sloan Kettering Cancer Center Rockville Centre, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center Commack, Commack

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

07920

Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge

All Listed Sponsors

collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER